These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39156358)

  • 41. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
    Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
    Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
    Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
    Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
    Zhou C; Klionsky Y; Treasure ME; Bruno DS
    Case Rep Oncol; 2019; 12(1):164-170. PubMed ID: 31043955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report.
    Kawazoe T; Ito S; Ohgaki K; Fujinaka Y; Funakoshi H; Otake A; Wang H; Morita K; Fushimi F; Ikeda Y
    Surg Case Rep; 2023 Mar; 9(1):51. PubMed ID: 36995570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
    Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
    Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
    J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
    Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
    Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.
    Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T
    Front Immunol; 2024; 15():1375136. PubMed ID: 39072325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
    Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
    Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China.
    Fan Z; Hui R; Ju H; Wu Y; Ma X; Song H; Liu Y; Rui M; Geng X; Zhao M; Xin Y; Wei D; Ren G
    Front Oncol; 2024; 14():1360657. PubMed ID: 38440229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset.
    Aoki S; Yasui M; Tajirika H; Terao H; Funahashi M; Ohta J
    Case Rep Oncol; 2020; 13(3):1490-1494. PubMed ID: 33564288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
    Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
    Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
    J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
    J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.
    Spathas N; Economopoulou P; Cheila M; Kotsantis I; Fanouriakis A; Kassara D; Psyrri A
    Front Oncol; 2018; 8():409. PubMed ID: 30319973
    [No Abstract]   [Full Text] [Related]  

  • 58. Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor.
    Mutoh T; Chikamatsu S; Sasaki T; Seino H; Sakamoto K; Kudo M
    JMA J; 2023 Oct; 6(4):552-555. PubMed ID: 37941715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report.
    Yang Y; Wu Q; Chen L; Qian K; Xu X
    Ann Transl Med; 2022 Apr; 10(7):424. PubMed ID: 35530956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.